Hypertension resource center

Resource Center

Supported by an independent educational grant from Daiichi Sankyo, Inc.

Abstracts

Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Drummond W, Sirenko YM, Ramos E, et al. Am J Cardiovasc Drugs. 2011;11:327-333.
Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.
Chrysant SG, Izzo JL Jr, Kereiakes DJ, et al. J Am Soc Hypertens. 2011. [Epub ahead of print]
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
Piller LB, Baraniuk S, Simpson LM, et al. Circulation. 2011;124:1811-1818.
Nondrug interventions for treatment of hypertension.
Woolf KJ, Bisognano JD. J Clin Hypertens (Greenwich). 2011;13:829-835.
Effect of Joint National Committee VII report on hospitalizations for hypertensive emergencies in the United States.
Deshmukh A, Kumar G, Kumar N, et al. Am J Cardiol. 2011;108:1277-1282.
Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report.
Opelz G, Döhler B. Am J Transplant. 2011;11:2483-2489.
Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.
Yoon C, Yang HS, Jeon I, et al. CMAJ. 2011;183:E1073-1084.
Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension.
Ukena C, Mahfoud F, Kindermann I, et al. J Am Coll Cardiol. 2011;58:1176-1182.
Restless legs syndrome and hypertension in middle-aged women.
Batool-Anwar S, Malhotra A, Forman J, Winkelman J, Li Y, Gao X. Hypertension. 2011;58:791-796.
Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni Health Study).
Gray L, Lee IM, Sesso HD, et al. J Am Coll Cardiol. 2011;58:2396-2403.
Disparities in blood pressure control within a community-based provider network: an exploratory analysis.
Romanelli RJ, Schiro TA, Jukes T, et al. Ann Pharmacother. 2011;45:1473-1482.
Drug-related hypertension and resistance to antihypertensive treatment: a call for action.
Rossi GP, Seccia TM, Maniero C, et al. J Hypertens. 2011;29:2295-22309.
Association between chlorthalidone treatment of systolic hypertension and long-term survival.
Kostis JB, Cabrera J, Cheng JQ, et al. JAMA. 2011;306:2588-2593.
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
Weir MR, Bakris GL, Weber MA, et al. Kidney Int. 2011. [Epub ahead of print]
Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations.
Bangalore S, Ley L. Expert Opin Pharmacother. 2012. [Epub ahead of print]
Antihypertensive and Metabolic Effects of Angiotensin Receptor Blocker/Diuretic Combination Therapy in Obese, Hypertensive African American and White Patients.
Ofili EO, Zappe DH, Purkayastha D, et al. Am J Ther. 2012. [Epub ahead of print]
Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project.
Allen N, Berry JD, Ning H, et al. Circulation. 2012;125:37-44.
Clinical features of paediatric pulmonary hypertension: a registry study.
Berger RM, Beghetti M, Humpl T, et al. Lancet. 2012. [Epub ahead of print]
Upper Normal Blood Pressures Predict Incident Atrial Fibrillation in Healthy Middle-Aged Men: A 35-Year Follow-Up Study.
Grundvold I, Skretteberg PT, Liestøl K, et al. Hypertension. 2012. [Epub ahead of print]
Mortality and Morbidity During and After the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Cushman WC, Davis BR, Pressel SL, et al. J Clin Hypertens (Greenwich). 2012;14:20-31.
Significance of White-Coat Hypertension in Older Persons With Isolated Systolic Hypertension: A Meta-Analysis Using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Population.
Franklin SS, Thijs L, Hansen TW, et al. Hypertension. 2012. [Epub ahead of print]
Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension.
Shibata H, Itoh H. Am J Hypertens. 2012. [Epub ahead of print]
Renal sympathetic denervation for treatment of electrical storm: first-in-man experience.
Ukena C, Bauer A, Mahfoud F, et al. Clin Res Cardiol. 2011.
Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea.
Witkowski A, Prejbisz A, Florczak E, et al. Hypertension. 2011;58:559-565.
Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety.
Rippy MK, Zarins D, Barman NC, et al. Clin Res Cardiol. 2011.
Renal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apnea.
Egan BM. Hypertension. 2011;58:542-543.
Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.
Symplicity HTN-1 Investigators. Hypertension. 2011;57:911-917
Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
Václavík J, Sedlák R, Plachy M, et al. Hypertension. 2011;57:1069-1075.
Endothelial-Dependent Flow-Mediated Dilation in African Americans With Masked-Hypertension.
Veerabhadrappa P, Diaz KM, Feairheller DL, et al. Am J Hypertens. 2011. [Epub ahead of print]
Hypertension management 2011: optimal combination therapy.
Sever PS, Messerli FH. Eur Heart J. 2011. [Epub ahead of print]
Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.
Kawut SM, Bagiella E, Lederer DJ, et al. Circulation. 2011;123:2985-2993.
Measuring blood pressure for decision making and quality reporting: where and how many measures?
Powers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone EZ. Ann Intern Med. 2011;154:781-788.
Hypertension in diverse populations: a New York State Medicaid clinical guidance document.
Wrobel MJ, Figge JJ, Izzo JL Jr. J Am Soc Hypertens. 2011;5:208-229.
Combination therapy as initial treatment for newly diagnosed hypertension.
Byrd JB, Zeng C, Tavel HM, et al. Am Heart J. 2011;162:340-346.
Comparative assessment of four blood pressure measurement methods in hypertensives.
Lamarre-Cliché M, Cheong NN, Larochelle P. Can J Cardiol. 2011;27:455-460.
Management of blood pressure in patients with diabetes.
Grossman E, Messerli FH. Am J Hypertens. 2011;24:863-875.
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Chang CH, Lin JW, Wu LC, et al. J Clin Oncol. 2011;29:3001-3007.
A hemodynamic study of pulmonary hypertension in sickle cell disease.
Parent F, Bachir D, Inamo J, et al. N Engl J Med. 2011;365:44-53.
Effect of dietary protein supplementation on blood pressure: a randomized, controlled trial.
He J, Wofford MR, Reynolds K, et al. Circulation¨. 2011;124:589-595.
Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice.
Corrao G, Nicotra F, Parodi A, et al. Hypertension. 2011. [Epub ahead of print]
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
Bisognano JD, Bakris G, Nadim MK, et al. J Am Coll Cardiol. 2011;58:765-773.
Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review).
Taylor RS, Ashton KE, Moxham T, et al. Am J Hypertens. 2011;24:843-53.
Improving Adherence With Amlodipine/Atorvastatin Therapy: IMPACT Study.
Oliver S, Jones J, Leonard D, et al. J Clin Hypertens (Greenwich). 2011;13:598-604.
Diagnosis and management of patients with white-coat and masked hypertension.
Mancia G, Bombelli M, Seravalle G, et al. Nat Rev Cardiol. 2011. [Epub ahead of print]
Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea.
Witkowski A, Prejbisz A, Florczak E, et al. Hypertension. 2011. [Epub ahead of print]
Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination: A Placebo-Controlled Study.
Drummond W, Sirenko YM, Ramos E, et al. Am J Cardiovasc Drugs. 2011. [Epub ahead of print]
Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
Matsuzaki M, Ogihara T, Umemoto S, et al. J Hypertens. 2011;29:1649-1659.
Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study.
Lovibond K, Jowett S, Barton P, et al. Lancet. 2011. [Epub ahead of print]
Decreased Slow Wave Sleep Increases Risk of Developing Hypertension in Elderly Men.
Fung MM, Peters K, Redline S, et al. Hypertension. 2011. [Epub ahead of print]
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.
Gupta AK, Nasothimiou EG, Chang CL, et al. J Hypertens. 2011. [Epub ahead of print]
Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.
Egan BM, Zhao Y, Axon RN, et al. Circulation. 2011;124:1046-1058
Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension.
Ukena C, Mahfoud F, Kindermann I, et al. J Am Coll Cardiol. 2011;58:1176-1182.
Should β Blockers No Longer Be Considered First-line Therapy for the Treatment of Essential Hypertension Without Comorbidities?
Elliott WJ, Childers WK. Curr Cardiol Rep. 2011. [Epub ahead of print]
Long-term effects of weight-reducing diets in hypertensive patients.
Siebenhofer A, Jeitler K, Berghold A, et al. Cochrane Database Syst Rev. 2011;9:CD008274.
Angiotensin receptor blockers: pharmacology, efficacy, and safety.
Taylor AA, Siragy H, Nesbitt S. J Clin Hypertens (Greenwich). 2011;13:677-686.
Progression Is Accelerated From Prehypertension to Hypertension in Blacks.
Selassie A, Wagner CS, Laken ML, et al. Hypertension. 2011. [Epub ahead of print]
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure.
Wain LV, Verwoert GC, O'Reilly PF, et al. Nat Genet. 2011. [Epub ahead of print]
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk.
The International Consortium for Blood Pressure Genome-Wide Association Studies, et al. Nature. 2011. [Epub ahead of print]
Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study.
Salles GF, Cardoso CR, Pereira VS, et al. J Hypertens. 2011;29:2014-2023.
Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion.
Stolarz-Skrzypek K, Kuznetsova T, Thijs L, et al; European Project on Genes in Hypertension (EPOGH) Investigators. JAMA. 2011;305:1777-1785.
Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial.
Václavík J, Sedlák R, Plachy M, et al. Hypertension. 2011. [Epub ahead of print]
Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.
de la Sierra A, Segura J, Banegas JR, et al. Hypertension. 2011;57:898-902.
Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.
Symplicity HTN-1 Investigators. Hypertension. 2011;57:911-917.
Renal denervation: a potential new treatment modality for polycystic ovary syndrome?
Schlaich MP, Straznicky N, Grima M, et al. J Hypertens. 2011;29:991-996.
Management of Blood Pressure in Patients With Diabetes.
Grossman E, Messerli FH. Am J Hypertens. 2011. [Epub ahead of print]
Use of Angiotensin receptor blockers and the risk of cancer.
Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Circulation. 2011;123:1729-1736. Epub 2011 Apr 11.
Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study.
Mahfoud F, Schlaich M, Kindermann I, et al. Circulation. 2011. [Epub ahead of print]
Prevalence of Resistant Hypertension in the United States, 2003-2008.
Persell SD. Hypertension. 2011. [Epub ahead of print]
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial.
Odili AN, Richart T, Thijs L, et al; On behalf of the NOAAH Investigators. Blood Press. 2011. [Epub ahead of print]
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.
Ofili EO, Oparil S, Giles T, et al. J Am Soc Hypertens. 2011. [Epub ahead of print]
Cardiovascular risk profile of young hypertensive patients: the OPENJOVEN study.
Martell-Claros N, Galgo-Nafria A. Eur J Cardiovasc Prev Rehabil. 2011. [Epub ahead of print]
Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients.
Kostka-Jeziorny K, Uruski P, Tykarski A. Blood Press. 2011;20:104-110.
Sugar-sweetened beverage, sugar intake of individuals, and their blood pressure: international study of macro/micronutrients and blood pressure.
Brown IJ, Stamler J, Van Horn L, et al; International Study of Macro/Micronutrients and Blood Pressure Research Group. Hypertension. 2011;57:695-701.
Therapy of hypertension in african americans.
Flack JM, Nasser SA, Levy PD. Am J Cardiovasc Drugs. 2011;11:83-92.
Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
Bekki H, Yamamoto K, Sone M, et al. Clin Cardiol. 2011;34:261-265.
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration. J Hypertens. 2011;29:623-635.
Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension.
Ferdinand KC, Weitzman R, Israel M, Lee J, Purkayastha D, Jaimes EA. J Am Soc Hypertens. 2011;5:102-113.
Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk.
Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Arch Intern Med. 2011;171:384-394.
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
Haller H, Ito S, Izzo JL Jr, et al; ROADMAP Trial Investigators. N Engl J Med. 2011;364:907-917.
Renal Denervation and Hypertension.
Schlaich MP, Krum H, Sobotka PA, Esler MD. Am J Hypertens. 2011. [Epub ahead of print]
Catheter-based renal sympathetic denervation reduces systolic blood pressure by 32 mm Hg in people with treatment-resistant hypertension.
Katholi RE, Rocha-Singh KJ. Evid Based Med. 2011. [Epub ahead of print]
Common secondary causes of resistant hypertension and rational for treatment.
Faselis C, Doumas M, Papademetriou V. Int J Hypertens. 2011;2011:236239.
Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis.
Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. JAMA. 2011;305:913-922.
Renal Artery Denervation for the Treatment of Hypertension: Opening up New Horizons.
Uder M, Schmid A, Titze S, Schmieder RE. Cardiovasc Intervent Radiol. 2011. [Epub ahead of print]
Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Int J Clin Pract. 2011;65:253-263.
Novel procedure- and device-based strategies in the management of systemic hypertension.
Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, de Leeuw PW. Eur Heart J. 2011;32:537-544.
The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea.
Drager LF, Pedrosa RP, Diniz PM, et al. Hypertension. 2011;57:549-555.
Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women.
Boggia J, Thijs L, Hansen TW, et al; International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes Investigators. Hypertension. 2011;57:397-405.
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Sandset EC, Bath PM, Boysen G, et al; SCAST Study Group. Lancet. 2011;377:741-750
Development and validation of a novel method to derive central aortic systolic pressure from the radial pressure waveform using an N-point moving average method.
Williams B, Lacy PS, Yan P, Hwee CN, Liang C, Ting CM. J Am Coll Cardiol. 2011;57:951-961.
The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers.
Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. CMAJ. 2011;183:303-307
Habitual intake of flavonoid subclasses and incident hypertension in adults.
Cassidy A, O'Reilly ÉJ, Kay C, et al. Am J Clin Nutr. 2011;93:338-347.
Culturally appropriate storytelling to improve blood pressure: a randomized trial.
Houston TK, Allison JJ, Sussman M, et al. Ann Intern Med. 2011;154:77-84.
Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system.
Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M. Circulation. 2011;123:209-215.
Assessment and management of hypertension in children and adolescents.
McCrindle BW. Nat Rev Cardiol. 2010;7:155-163.
Combination therapy in hypertension.
Gradman AH, Basile JN, Carter BL, Bakris GL. J Am Soc Hypertens. 2010;4:90-98.
Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.
Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL. J Hum Hypertens. 2010 Mar 4. [Epub ahead of print].
Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension.
Bekki H, Yamamoto K, Sone M, et al. Oxid Med Cell Longev. 2010;3(5).
Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers.
Kenny LC, Broadhurst DI, Dunn W, et al. Hypertension. 2010;56:741-749.
Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008.
Yoon SS, Ostchega Y, Louis T. NCHS Data Brief. 2010;(48):1-8.